Scholarlink

Purpose <p>Distinguishing pseudoprogression (PsP) from true progression (TP) in glioblastoma (GBM) remains a diagnostic challenge, yet is essential for guiding treatment and counseling prognosis. This study retrospectively assessed the incidence, clinical predictors, and survival impact of PsP compared to TP.</p> Methods <p>Patients with surgically treated GBM and postoperative (chemo)radiotherapy in two Dutch hospitals (2006–2021) were included. Reports of magnetic resonance imaging (MRI) scans performed 4 months post-radiotherapy and at 3-month intervals, as well as reports of MRI scans prompted by neurological decline, were evaluated for PsP, TP, or mixed response (MR). Associations with clinical, tumor, and treatment characteristics and overall survival (OS) were analyzed.</p> Results <p>Of 424 GBM patients, 175 were eligible for PsP analysis. The incidence of PsP was 29.1%, and PsP was associated with longer OS (median 16.6 months, 95% CI 12.0–21.2) compared to MR (14.1 months, 95% CI 11.1–17.2) and TP (11.6 months, 95% CI 10.0–13.2; <i>p</i> = 0.010). However, PsP occurring &lt; 4 months after chemoradiotherapy was linked to shorter OS (11.3 months) than PsP &gt; 4 months (17.4 months; <i>p</i> = 0.027). Male sex was significantly associated with outcome in univariate analysis, showing a trend toward significance in multivariate analysis. Treatment completion remained significant only in the multivariate model.</p> Conclusion <p>PsP is associated with improved survival compared to TP, though early-onset PsP portends poorer outcomes. None of the evaluated factors were a significant predictor of PsP in both univariate and multivariate analyses. Future research should focus on validating molecular markers, and refining PsP definitions using standardized criteria.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical predictors of pseudoprogression in glioblastoma: a retrospective cohort analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月24日

查看全文
  • L. J. N. Hoosemans,
  • L. F. Panayotopoulos,
  • S. M. J. van Kuijk,
  • M. Verduin,
  • M. H. M. E. Anten,
  • R. C. O. S. Pasmans,
  • J. M. Schellekens,
  • S. M. H. Huijs,
  • S. R. Verhoeff,
  • F. W. P. J. van den Berkmortel,
  • L. C. Steggink,
  • L. Ackermans,
  • O. E. M. G. Schijns,
  • O. P. M. Teernstra,
  • K. Hovinga,
  • J. C. Beckervordersandforth,
  • I. Compter,
  • D. B. P. Eekers,
  • A. A. Postma,
  • M. A. Vooijs,
  • M. P. G. Broen,
  • A. Hoeben

摘要

Purpose

Distinguishing pseudoprogression (PsP) from true progression (TP) in glioblastoma (GBM) remains a diagnostic challenge, yet is essential for guiding treatment and counseling prognosis. This study retrospectively assessed the incidence, clinical predictors, and survival impact of PsP compared to TP.

Methods

Patients with surgically treated GBM and postoperative (chemo)radiotherapy in two Dutch hospitals (2006–2021) were included. Reports of magnetic resonance imaging (MRI) scans performed 4 months post-radiotherapy and at 3-month intervals, as well as reports of MRI scans prompted by neurological decline, were evaluated for PsP, TP, or mixed response (MR). Associations with clinical, tumor, and treatment characteristics and overall survival (OS) were analyzed.

Results

Of 424 GBM patients, 175 were eligible for PsP analysis. The incidence of PsP was 29.1%, and PsP was associated with longer OS (median 16.6 months, 95% CI 12.0–21.2) compared to MR (14.1 months, 95% CI 11.1–17.2) and TP (11.6 months, 95% CI 10.0–13.2; p = 0.010). However, PsP occurring < 4 months after chemoradiotherapy was linked to shorter OS (11.3 months) than PsP > 4 months (17.4 months; p = 0.027). Male sex was significantly associated with outcome in univariate analysis, showing a trend toward significance in multivariate analysis. Treatment completion remained significant only in the multivariate model.

Conclusion

PsP is associated with improved survival compared to TP, though early-onset PsP portends poorer outcomes. None of the evaluated factors were a significant predictor of PsP in both univariate and multivariate analyses. Future research should focus on validating molecular markers, and refining PsP definitions using standardized criteria.